Clinical Trials Unit

Prof. Dr. Matthis Synofzik

Research areas/focus

Prof. Synofzik spearheads an innovative molecular precision medicine approach to neurodegenerative diseases by developing and implementing systematic translational programs from n-of-1 to common neurodegenerative diseases. These proceed from next-generation genomics profiling via molecular fluid biomarker and digital-motor profiling to trial-readiness and first-in-human treatments. This is includes pioneering a disruptive, world-first scalable platform approach of patient-customized ASO therapies across a broad number of genetic neurodegenerative diseases.

As part of this molecular precision medicine approach, his contributions to the field so far include:

  • development and application of next-generation genomics and transcriptomics, disease progression models, protein fluid biomarker profiling, sensor digital-motor biomarkers, and trial-readiness platforms of neurodegenerative diseases (frontotemporal dementia, Alzheimer dementia, ataxias, spasticity diseases);
  • aggregation and analysis of large-scale next-generation genomics datasets (whole exome, whole genome, transcriptome) in neurological disease, including built-up of the currently world’s largest NGS database for ataxia NGS datasets (PREPARE GENESIS, >3000 NGS datasets)
  • developed techniques and protocols for capture of digital-motor outcomes by body-worn sensors and smartphones for neurodegenerative diseases (e.g. ataxias, HSPs), including remote real-life capture allowing for high ecological validity
  • developed multimodal progression models for neurodegenerative diseases (e.g. frontotemporal dementias, ataxias) including fluid protein biomarker, clinical and imaging trajectories
  • pioneered individualized RNA therapies for ultrarare neurological diseases, with innovative patient-customized anti-sense oligonucleotides (ASOs), co-leading a European platform (1 Mutation 1 Medicine) that includes streamlined biological, clinical and regulatory development of patient-customized antisense oligonucleotides (ASOs), with implementation of first n-of-1 ASO treatment in Europe

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: